3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Ovarian Neoplasms
9
Neoplasms
2
Fallopian Tube Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Glioblastoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Paclitaxel
23
Carboplatin
22
Capecitabine
18
Gemcitabine
16
130-nm albumin-bound paclitaxel
16
pembrolizumab
14
Cyclophosphamide
12
atezolizumab
9
Epirubicin
9
sacituzumab govitecan
8
Albumin-Bound Paclitaxel
8
eribulin
6
Vinorelbine
6
Drug Therapy
6
Doxorubicin
6
camrelizumab
4
Docetaxel
4
Cisplatin
4
Injections
3
pegfilgrastim
2
olaparib
2
famitinib
2
Filgrastim
2
Everolimus
2
veliparib
1
trilaciclib
1
toripalimab
1
taxane
1
niraparib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Triple Negative Breast Neoplasms
×
niraparib
×
Clear all
NCT04915755
2025-07-16
ZEST
GlaxoSmithKline
Phase 3
Active not recruiting
40 enrolled
13 charts